introduction
Adverse events associated with medicines are common and place a significant burden on the healthcare system in terms of both health outcomes and cost. It is estimated that 10% of patients visiting general practices will have had an adverse drug event in the previous six months. 1 This affects more than 1.5 million people per year 2 and results in at least 190 000 hospital admissions annually. 3 Adverse drug events include errors in the way the medicine is used, and adverse drug reactions that result from the pharmacological properties of the drug itself, either alone or in combination with other medicines. Recognising and preventing all types of adverse drug events is therefore a high priority. Failure to recognise an adverse drug reaction has the potential to further compound poor health, particularly when the reaction is mistaken for a symptom of a new health problem.
If this is subsequently treated with another drug a prescribing cascade results. This can make the original adverse drug reaction even more difficult to recognise and puts the patient at further risk of adverse reactions.
what is a prescribing cascade?
A prescribing cascade occurs when a new medicine is prescribed to 'treat' an adverse drug reaction associated with another medicine, in the mistaken belief that a new medical condition requiring treatment is present (Fig. 1) . 4 Prescribing cascades may also occur when an adverse drug reaction is anticipated. An example is the prescription of a proton pump inhibitor to reduce gastrointestinal adverse effects associated with non-steroidal anti-inflammatory drugs (NSAIDs).
Prescribing cascades resulting from both unrecognised and recognised adverse reactions put the patient at further risk of harm.
antibiotics, and medicines for nausea. Table 1 shows some of the prescribing cascades reported with these medicines.
The cascades include the prescription of prochlorperazine to counteract drug-induced dizziness, antihypertensives to treat NSAID-induced hypertension and levodopa to manage metoclopramide-induced movement disorder. Many other medicines may be involved in prescribing cascades, but many adverse drug reactions go unrecognised and unreported.
Potential for harm
Prescribing cascades can exacerbate the harmful effects of an unrecognised adverse drug reaction. A study conducted in Australian veterans found an increased rate of prochlorperazine prescription following the prescription of drugs which cause dizziness, such as antihypertensives. 5 Prochlorperazine itself is associated with postural hypotension which may exacerbate any hypotensive effect. This may account for the increased rate of hospitalisation for hip fracture which was observed after patients started prochlorperazine. 5 Although the absolute risk of hip fracture was small, the relative risk of having a hip fracture after starting prochlorperazine increased by nearly 50%. 5 Hip fracture is associated with increased morbidity and mortality, 6 highlighting the potential for serious harm associated with this prescribing cascade.
A published report illustrates the potential for harm arising from a prescribing cascade, involving an antihypertensive drug. 7 An elderly woman developed a cough, which was not recognised as being caused by the ACE inhibitor she was taking, so she The elderly, those using multiple medicines, women, and people using 'high risk medicines', including cardiovascular drugs, NSAIDs, anticoagulants and antibiotics, are at higher risk of adverse drug reactions. 1, 8, 9 In the elderly, specific drug classes -anticholinergics, antipsychotics, benzodiazepines, hypnotics and sedativesincrease the risk of adverse drug reactions. 9 Elderly people may be at higher risk of prescribing cascades than younger people because the adverse drug reaction is more likely to be misinterpreted as the onset of a new medical condition. 4 For example, a movement disorder induced by metoclopramide may be misinterpreted as Parkinson's disease, but this misinterpretation would be less likely in a young person as Parkinson's disease is less prevalent in younger people. 4 Patients are at the highest risk of having an adverse drug reaction soon after starting a medicine. Approximately 90% 
Preventing the prescribing cascade
Quality use of medicines is the judicious selection of management options, appropriate choice of medicines when a medicine is considered necessary, and safe and effective use Medicines Information and should be provided to patients whenever a medicine is started or the dose changed. Home medicines reviews should also be considered for patients who are at risk of adverse drug reactions, and therefore at risk of prescribing cascades. These reviews increase the identification and resolution of medicine-related problems, 14 and reduce medicine-related hospitalisations. 15, 16 
Conclusion
Prescribing cascades have the potential to result in serious harm My casual observation seems to give the impression that a significant number of these patients are Asian people.
Anecdotally, diabetes and lipid control in many of these patients improved when they started donating blood regularly.
My hypothesis is that:
there are more genotypes yet to be discovered which are responsible for elevated ferritin levels in Asian people this (undetected and untreated) elevated ferritin may deposit in the pancreas and liver, and to some extent contributes to the high rate of diabetes and fatty livers that are so prevalent in Asian people.
Unfortunately, this is just a hunch and I do not have the detailed breakdown of these tests.
Chenault Doug Lee General practitioner Erindale Medical Practice, ACT
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